INTRODUCTION

GPFX is a new quinolone (NQ) antibiotic and has a high lipophilicity compared with other
NQs. The distinct pharmacokinetic features of GPFX include its higher distribution to various tissues, especially lung (Akiyama et al., 1995a , b, Nakajima et al., 2000 , Suzuki et al., 2002 although the exact mechanism for this has not yet been fully clarified. We have previously reported that GPFX specifically binds to phosphatidylserine among various phospholipids, and that the tissue distribution of GPFX is well correlated with the tissue phosphatidylserine content (Suzuki et al., 2002) . However, membrane transport processes such as an active influx and/or efflux may also contribute to the tissue distribution of GPFX. In actual fact, the distribution of GPFX and other NQs to the brain is restricted because of the limited permeability of these compounds through the blood-brain barrier (BBB) by active efflux transporters such as P-glycoprotein (P-gp), an mdr1 gene product (Tsuji et al., 1988; Ooie et al., 1996 , 1997 , Murata et al., 1999 , Tamai et al, 2000 .
In mice, mdr1a is highly expressed in intestine, brain, testis and lung while mdr1b is highly expressed in adrenal gland, pregnant uterus and ovary. Both genes are expressed in many other tissues (Croop et al., 1989; Schinkel et al., 1994 Schinkel et al., , 1995 . Transport studies with an MDR1-transfected cell line demonstrated that GPFX is a substrate of P-gp (Naruhashi et al., 2001) .
These findings suggest possible roles for P-gp in the secretion and/or distribution of GPFX in these organs. Indeed, several NQs including GPFX have been reported to be actively secreted across the apical membrane of human intestinal epithelial Caco-2 cells, and P-gp possibly limits the bioavailability of these drugs in vivo (Griffiths et al., 1993 , 1994 , Naruhashi et al., 2001 Yamaguchi et al., 2000 Yamaguchi et al., , 2001 Yamaguchi et al., , 2002 . Transport studies with kidney epithelial cell line LLC-PK 1 monolayers suggested that P-gp and/or some other transport system plays a role in the renal tubular JPET #65201
In contrast to the many studies on P-gp described above, the involvement of multidrug resistance-associated proteins (Mrp) in the disposition of GPFX has not yet been fully characterized. Mrp1 is also expressed in ubiquitous organs, but its expression in the liver was minimal in normal condition. Using gene-deficient mice (mrp1(-/-)), Mrp1 was proposed to be involved in the efflux of etoposide from the cerebrospinal fluid space (Wijnholds et al., 2000) .
Mrp1 is highly expressed in the lung and also expressed in the epithelial lining bronchi and bronchioles (Stride et al., 1996) . This suggests that the involvement of Mrp1 in the distribution of its substrate to the lung needs to be investigated. Mrp2 is, on the other hand, highly expressed in the liver, followed by the kidney and small intestines, and proposed to be mainly involved in the biliary excretion of various organic anions (Borst and Elferink 2002; Payen et al., 2002; Suzuki and Sugiyama 2002) . Using Mrp2-deficient rats, we have previously reported that the biliary excretion of GPFX is partially mediated by Mrp2 (Sasabe et al., 1998) . Such involvement of Mrp2 has also been reported for the biliary excretion of HSR-903, another NQ (Murata et al., 1998) .
In view of overlapping substrate specificity of Mrp1 with Mrp2 and the expression profile of Mrp1 in ubiquitous tissues, we have investigated here the possible contribution of Mrp1 to the tissue distribution and excretion of GPFX using mrp1(-/-) mice. We have examined the distribution of GPFX to many organs in mdr1a(-/-) and mdr1a/1b(-/-) mice to clarify the different roles of both Mrp1 and Mdr1 in the distribution of GPFX.
.
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MATERIALS AND METHODS
Materials
[
14 C]-GPFX, (±)-1-cyclopropyl-6-fluoro-1,4-dihydro-5-methyl-7-(3-methyl-1-piperazinyl)
-4-oxo-3-quinolinecarboxulic acid monohydrochloride (specific activity 3.00 MBq/mg, radiochemical purity 97.1%) and (27: 73 (v/v) ).
Urinary and biliary excretions of GPFX.
The bile duct and penis were connected to a polyethylene catheter under ether anesthesia.
Bile and urine were collected over a period of up to 48 hr after drug administration. The radioactivity in bile and urine was counted and unchanged GPFX and its metabolites were determined, after centrifugation, using the HPLC system described above.
Distribution of [ 14 C]-GPFX to the pulmonary airspace
The distribution of GPFX to lung compartments such as alveolar macrophages and epithelial lining fluid (ELF) was determined by a slight modification of the method described by Alblas and Furth (1979) . Briefly, [
mice, mdr1a/1b(-/-) and mdr1a/1b(+/+) mice through a tail vein at a dose of 5 mg/kg. Blood samples were collected from the inferior vena cava at designated times. The mice were killed by severing the inferior vena cava and aorta, and then, the trachea was cannulated with a short length of intravenous catheter tubing (0.80 mm I.D., Terumo, Tokyo, Japan). One mL ice-cold Mg 2+ -free phosphate buffered saline (PBS) containing 1 mM EDTA was gently instilled into the lung. After gently rubbing the lung, the fluid was slowly withdrawn. The alveolar lavage was repeated 5
times. The lavage fluids were pooled, and centrifuged at 400xg for 10 min to obtain macrophage cells. The cell pellet was washed twice with Mg 2+ -free PBS containing 1 mM EDTA and then the cells were re-suspended in the same buffer. Viability counts were performed by trypan blue exclusion. After the lavage, the lung was excised immediately and homogenized with 1 mL of Mg 2+ -free PBS. To measure the radioactivity in the homogenate, cell suspension and lavage fluid, each sample was solubilized with 1 mL tissue solubilizing solution. The lysate was neutralized with 1 mL pH adjusting solution and then scintillation cocktail was added to the vial. The unchanged GPFX in the lung compartments was determined by HPLC connected to a flow scintillation analyzer as described above. Protein concentrations in the lung compartments were determined by the method of Lowry (1951), using a protein assay kit (Bio-Rad, Hercules, CA) with bovine serum albumin as a standard.
Determination of blood flow rate
Under ether anesthesia, the abdomens were incised, and the blood flow rate at the portal vein was measured using an electromagnetic flow meter (Transonic Systems Inc. Ithaca, NY).
Plasma protein binding of [ 14 C]-GPFX in vitro
Plasma protein binding of GPFX was determined by ultrafiltration. Initially, a filtration tube (Centrifree YM30, Millipore, MA), in which blank plasma had been placed, were centrifuged to obtain the filtrate (1,800xg, 20 min). Another filtration tube was filled with the filtrate obtained and then centrifuged. This pretreatment of the filtration tube reduced any non-specific adsorption of GPFX to the membrane filter. Plasma samples with [ 14 C]-GPFX (final concentration; 0.02 and 2 µg/mL) were placed in the pretreated filtration tubes, and then incubated at 37 for 5 min.
The plasma was centrifuged (1,800xg, 5 min) to yield a filtrate containing the unbound compound.
The radioactivity in the plasma and filtrate was counted to determine the total and free concentration, respectively.
This article has not been copyedited and formatted. The final version may differ from this version. ethylacetate. After centrifugation, the organic layer was evaporated to dryness. The residue was dissolved in 100 µL methanol, and an aliquot was subjected to HPLC with a TSKgel ODS-80Ts column (4.6 mm I.D. x15 cm). Separation was achieved by a mobile phase of acetonitrile and 0.1% trifluoroacetic acid (1: 3, v/v) at a flow rate of 1 mL/min. DNP-SG was detected at 365 nm and quantified from the peak area using a standard curve.
To determine the efflux of GPFX, the apical and basal medium were first replaced with HBSS/5% FBS with and without 5-6.25 µM [ 14 C]-GPFX, respectively. After preincubation for 1 hr at 23 o C, the cells were washed twice with ice-cold PBS, and sequential efflux was initiated by replacing both sides with HBSS/5% FBS. At designated times, 500 µL aliquots of the medium were taken from both sides to determine GPFX. At the last sampling point, the cell monolayer was washed twice with ice-cold PBS and dried up an air current. Then, 0.1 N NaOH was added to JPET #65201
Data Analysis
To obtain pharmacokinetic parameters, the plasma concentration data for unchanged GPFX were fitted to a 2-compartment model using a pharmacokinetic software package (WinNonlin version 3.01; Pharsight corporation, NC unchanged GPFX in plasma was determined and compared with that in control mice. GPFX was biexponentially eliminated from plasma (Fig. 1) . The plasma concentration profile in mrp1 (-/-) was very similar to that in mrp1(+/+) whereas that in mdr1a(-/-) and mdr1a/1b(-/-) was higher than that in mdr1a/1b(+/+) (Fig. 1) .
Tissue distributions of [
C]-GPFX in mrp1(-/-) and mrp1(+/+) mice
The tissue concentrations of unchanged GPFX following a single intravenous administration of [ 14 C]-GPFX to mrp1(-/-) and mrp1(+/+) were examined. In preliminary studies, the concentrations of radioactivity in each tissue had almost reached equilibrium with that in plasma within 4 hr of intravenous administration and, therefore, the tissue-to-plasma concentration ratio during the ß-Phase (K p,ß ) was determined as the mean value of K p at 4 and 6 hr (Table 1) . In mrp1(+/+), a higher K p,ß was observed in lung, liver, kidney, pancreas, small intestine and large intestine whereas the K p,ß value in brain and fat was relatively small (Table 1) . The K p,ß in trachea, heart, kidney, spleen and brown fat of mrp1(-/-) was significantly higher than that in mrp1(+/+) whereas that in other tissues was fairly similar for each strain (Table 1) .
Tissue distributions and excretion of GPFX in mdr1a(-/-), mdr1a/1b(-/-) and mdr1a/1b(+/+) mice
The K p,ß values in the brain of mdr1a(-/-) and mdr1a/1b(-/-) were 2.4 times higher than that in mdr1a/1b(+/+) ( Table 2 ). This result is compatible with a previous report (Tamai et al., 2000; Yamaguchi et al., 2002) and supports the hypothesis that Mdr1a might contribute to the limited distribution of GPFX to the brain. In other tissues except the large intestine, the K p,ß values in mdr1a(-/-) and mdr1a/1b(-/-) were comparable with that in mdr1a/1b(+/+) ( Table 2 ). The distribution of LVFX, another new quinolone analogue, was also examined in these mice strains to examine whether the observed difference in tissue distribution is specific for GPFX. (Table 2) , confirming the observation by Tamai et al (2000) . In addition, no difference among these strains was found for all the other tissues examined ( The CL tot,p of GPFX in mdr1a(-/-) and mdr1a/1b(-/-) was reduced by about 30% and 20 %, respectively, compared with that in mdr1a/1b(+/+) ( Table 3) . The CL urine,p of GPFX in mdr1a (-/-) was significantly smaller than that in mdr1a/1b(+/+) ( Table 3) . The CL urine,p of GPFX in mdr1a/1b(-/-), compared with that in mdr1a/1b(+/+), was reduced by about 30% although this difference was not statistically significant (Table 3) . The CL other,p of GPFX was also lower in mdr1a(-/-) and mdr1a/1b(-/-) compared with the control mice (Table 3 ). Since the hepatic clearance (sum of CL bile,p and CL met,p ) was not very different from the hepatic plasma flow rate, we also measured the blood flow rate in the portal vein of each strain and found that the hepatic blood flow in mdr1a /1b(-/-) was slightly lower than that in mdr1a/1b(+/+) ( Table 3 ). The plasma protein binding of [ 14 C]-GPFX at 2 µg/mL was measured in each strain (Table 3) . Although there was a statistically significant difference between mdr1a/1b(+/+) and mdr1a/1b(-/-) at 2 µg/mL, this difference was small (Table 3 ). In addition, the plasma protein binding of GPFX was low, at most 35-40% (Table 3) .
Distribution of [ 14 C]-GPFX to pulmonary airspace
To characterize the distribution mechanism of GPFX to its pharmacological target site, unchanged GPFX was determined in lung parenchyma cells and pulmonary airspaces including ELF and macrophages after intravenous administration (Fig. 2) . At 4-8 hr after administration to both mdr1a/1b(-/-) and mdr1a/1b(+/+), the radioactivity in the pulmonary airspaces including lavage fluid accounted for 11-13% of the total radioactivity distributed to the whole lung. No difference between mdr1a/1b(-/-) and mdr1a/1b(+/+) was observed in the distribution of GPFX to the pulmonary airspaces. The alveolar macrophage-to-plasma concentration ratio of unchanged GPFX in mdr1a/1b(-/-) was significantly lower than that in mdr1a/1b(+/+) although this difference was not very marked (Fig. 2) . The ELF-to-plasma concentration ratio in mdr1a/1b(-/-) was not statistically different, and almost identical to that in mdr1a/1b(+/+) (Fig. 2) . The distribution of GPFX to the pulmonary airspace was also examined in mrp1(-/-) at 4 hr after intravenous administration.
No statistically significant difference was observed in the distribution ratio to the pulmonary airspaces, alveolar macrophages and ELF between mrp1(-/-) and mrp1(+/+) ( Fig. 2A) . 
Efflux of GPFX and DNP-SG by LLC-MRP1 cells
Although GPFX is reported to be a substrate of P-gp (Naruhashi et al., 2001) , no information is available on whether GPFX is transported by MRP1 or not. To support the hypothesis that Mrp1 is involved in GPFX distribution to several tissues, resulting in the increase in the K p,ß of the corresponding tissues in mrp1(-/-), a transport study using LLC-MRP1 was performed to examine whether GPFX is a substrate of MRP1 or not. Firstly, to exclude the possibility of depolarization in LLC-PK1 cells during the culture period, efflux of DNP-SG, a typical substrate of MRP1, to the basal and apical sides was examined in the present study (Fig. 3A) . The efflux of DNP-SG to the basal side in LLC-MRP1 during the incubation with CNDB was 2.3-fold higher than that in LLC-PK1 (Fig. 3A) . On the other hand, the efflux to the apical side in LLC-MRP1 was close to that in LLC-PK1 (Fig. 3A) . The total amount of DNP-SG recovered both in the cells and the medium after the 20 min efflux study, representing the conjugating activity of CDNB to DNP-SG, was 1.4-fold higher in LLC-PK1 than that in LLC-MRP1 (Fig. 3, legend) . The efflux of DNP-SG specifically to the basal side is similar to that obtained in LLC-pK1 cells at 3 days after seeding as described by Evers et al (1996) . Then, the efflux of GPFX in LLC-MRP1 cells was examined (Fig.   3B ). The intracellular accumulation of unchanged GPFX after 1 hr loading in LLC-MRP1 were almost equal to that in LLC-PK1 (Fig. 3, legend) . The efflux of GPFX to the basal side in LLC-MRP1 was higher than that in LLC-PK1, and the efflux to the apical side was almost identical in between LLC-MRP1 and LLC-PK1 (Fig. 3B) . Considering that MRP1 is expressed in the basal JPET #65201
On the other hands, the plasma concentration of GPFX in mrp1(-/-) was similar to that in mrp1(+/+) (Fig. 1) . Therefore, the contribution of Mrp1 to the excretion of GPFX in mice might be minor. We have previously reported that the biliary excretion of GPFX is partially mediated by Mrp2. Therefore, the contribution of Mrp1 to the excretion process of GPFX in mice might be minor although the biliary excretion of GPFX is partially mediated by Mrp2 (Sasabe et al., 1998).
Wijnholds et al (2000) demonstrated a significant increase in radioactivity in mrp1(-/-) after the administration of [ 3 H]-etoposide, MRP1 substrate, in heart and brown adipose tissue, compared with mrp1(+/+). This finding could be compatible with the possible involvement of Mrp1 in the distribution of GPFX to these two tissues (Table 1) . However, we observed no difference in the distribution of E 2 17G, another typical substrate of MRP1, to these tissues as well as kidney and spleen between the two strains when we determined the parent compound by HPLC at 10 min after its injection (data not shown). Thus, the involvement of transporters in tissue distribution is highly substrate-dependent, and a number of other transporters should also be considered in order to appreciate the whole picture as far as the distribution mechanism of GPFX is concerned.
Wijnholds (2000) Both Mdr1 and Mrp1 are reported to be expressed in lung (Croop et al., 1989; Schinkel et al., 1994 Schinkel et al., , 1995 Stride et al., 1996) . To understand the possible functions of these transporters for the disposition of GPFX in its target organs, GPFX concentrations in alveolar macrophages and ELF were compared among mdr1a/1b(-/-), mrp1(-/-) and wild-type mice. The distribution to alveolar macrophages, the lung parenchyma cells and ELF was relatively similar for each strain (Fig. 2) . A significant difference was observed in the alveolar macrophage-to-plasma concentration ratio between mdr1a/1b(-/-) and mdr1a/1b(+/+) (Fig. 2B ). Considering that this difference was significant only at 4 hr after injection (Fig. 2B) , further studies are needed to prove any involvement of mdr1 in GPFX distribution. Thus, although GPFX is a substrate of MDR1 and MRP1, these transporters do not play a major role in the higher distribution of GPFX to the lung. On the other hand, the possible contribution of MDR1 and MRP1 to GPFX distribution to the brain and heart, respectively, should also be noted since NQs exhibit an unexpected side effect in these organs. Various dugs can sometimes cause cardiac adverse effects, for instance, prolongation of the QT intervals, which is commonly considered to be associated with the distribution to myocardial tissues. The present findings should promote the further investigation of the involvement of the Mrp family in drug distribution to the heart and its relevance to this potential side effect.
In conclusion, GPFX is a substrate of MRP1 and its distribution to a number of several tissues, including heart, trachea, kidney and spleen, is restricted partially by the efflux by GPFX whereas MDR1 is involved in the efflux of GPFX from the brain and excretion into the urine.
Thus, multiple ABC transporters, MDR1, MRP1 and MRP2, are involved in the distribution of GPFX, thereby restricting its exposure both to pharmacological and toxicological targets such as the bile, brain and heart.
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